Zafgen Inc. (NASDAQ:ZFGN)’s share price was up 2.6% during mid-day trading on Friday . The stock traded as high as $6.72 and last traded at $6.64, with a volume of 103,536 shares trading hands. The stock had previously closed at $6.47.

Several equities analysts have recently issued reports on ZFGN shares. FBR & Co reissued a “buy” rating and issued a $20.00 price objective on shares of Zafgen in a report on Monday, April 4th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $19.00 price target on shares of Zafgen in a report on Tuesday, April 5th. Leerink Swann reaffirmed a “hold” rating and issued a $6.00 price target on shares of Zafgen in a report on Monday, April 11th. Finally, Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a report on Thursday, May 12th. Four research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $11.94.

The stock’s market capitalization is $182.18 million. The company’s 50-day moving average price is $6.43 and its 200 day moving average price is $6.58.

Zafgen (NASDAQ:ZFGN) last issued its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.09. During the same period in the previous year, the business posted ($0.53) EPS. Equities analysts expect that Zafgen Inc. will post ($2.81) EPS for the current fiscal year.

An institutional investor recently bought a new position in Zafgen stock. Oxford Asset Management acquired a new stake in Zafgen Inc. (NASDAQ:ZFGN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 236,362 shares of the biopharmaceutical company’s stock, valued at approximately $1,497,000. Oxford Asset Management owned 0.87% of Zafgen as of its most recent SEC filing.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.